COMMONWEALTH OF PENNSYLVANIA PUBLIC SCHOOL EMPLS RETRMT SYS - AMPHASTAR PHARMACEUTICALS IN ownership

AMPHASTAR PHARMACEUTICALS IN's ticker is AMPH and the CUSIP is 03209R103. A total of 119 filers reported holding AMPHASTAR PHARMACEUTICALS IN in Q4 2019. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
COMMONWEALTH OF PENNSYLVANIA PUBLIC SCHOOL EMPLS RETRMT SYS ownership history of AMPHASTAR PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$1,171,687
-52.1%
25,477
-40.1%
0.01%
-47.4%
Q2 2023$2,446,096
+63.4%
42,563
+6.6%
0.02%
+46.2%
Q1 2023$1,496,850
+132364.6%
39,916
-1.1%
0.01%
+30.0%
Q4 2022$1,130
-99.9%
40,346
+15.8%
0.01%0.0%
Q3 2022$979,000
-17.9%
34,834
+1.6%
0.01%
-23.1%
Q2 2022$1,192,000
+4.6%
34,275
+7.9%
0.01%
+18.2%
Q1 2022$1,140,000
+75.7%
31,763
+14.1%
0.01%
+57.1%
Q4 2021$649,000
+21.8%
27,847
-0.7%
0.01%
+16.7%
Q3 2021$533,000
-6.0%
28,042
-0.4%
0.01%0.0%
Q2 2021$567,000
+9.7%
28,148
-0.2%
0.01%0.0%
Q1 2021$517,000
-9.3%
28,209
-0.4%
0.01%
-25.0%
Q4 2020$570,000
+7.1%
28,335
-0.1%
0.01%
-20.0%
Q3 2020$532,000
+39.6%
28,373
+67.1%
0.01%
+42.9%
Q2 2020$381,000
+48.8%
16,976
-1.5%
0.01%
+16.7%
Q1 2020$256,000
+14.3%
17,240
+48.4%
0.01%
+50.0%
Q4 2019$224,000
-3.4%
11,616
-0.7%
0.00%0.0%
Q3 2019$232,000
-9.0%
11,693
-3.3%
0.00%0.0%
Q2 2019$255,000
+5.4%
12,089
+1.9%
0.00%0.0%
Q1 2019$242,000
+2.5%
11,866
+0.1%
0.00%
-20.0%
Q4 2018$236,00011,8550.01%
Other shareholders
AMPHASTAR PHARMACEUTICALS IN shareholders Q4 2019
NameSharesValueWeighting ↓
EAM Investors, LLC 173,018$3,187,0000.42%
GLOBEFLEX CAPITAL L P 50,686$934,0000.23%
KALMAR INVESTMENTS INC /DE/ 240,648$4,433,0000.23%
ESSEX INVESTMENT MANAGEMENT CO LLC 63,661$1,173,0000.19%
OBERWEIS ASSET MANAGEMENT INC/ 27,200$501,0000.15%
Invictus RG 11,950$220,0000.15%
ACADIAN ASSET MANAGEMENT LLC 1,502,151$27,668,0000.13%
FOX RUN MANAGEMENT, L.L.C. 12,600$232,0000.12%
Piermont Capital Management Inc. 26,153$482,0000.11%
FEDERATED HERMES, INC. 1,344,684$24,769,0000.07%
View complete list of AMPHASTAR PHARMACEUTICALS IN shareholders